Discounted Cash Flow (DCF) Analysis Unlevered

Celularity Inc. (GXGX)

$ 10.2
2.18 27.18%

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
Revenue (%)
EBITDA -------
EBITDA (%)
EBIT -------
EBIT (%)
Depreciation -------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash -------
Total Cash (%)
Account Receivables -------
Account Receivables (%)
Inventories -------
Inventories (%)
Accounts Payable -------
Accounts Payable (%)
Capital Expenditure -------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 10.2
Beta 0.000
Diluted Shares Outstanding 8.02
Cost of Debt
Tax Rate 7.86
After-tax Cost of Debt 4.61%
Risk-Free Rate
Market Risk Premium
Cost of Equity 2.460
Total Debt -
Total Equity 81.76
Total Capital 81.76
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
EBITDA -------
EBIT -------
Tax Rate 21.01%7.86%14.43%14.43%14.43%14.43%14.43%
EBIAT -------
Depreciation -------
Accounts Receivable -------
Inventories -------
Accounts Payable -------
Capital Expenditure -------
UFCF -------
WACC
PV UFCF -------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 2.46
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -0
Equity Value -
Shares Outstanding 8.02
Equity Value Per Share -